Bamco Inc. NY Has $2.90 Million Position in Elanco Animal Health Incorporated $ELAN

Bamco Inc. NY lessened its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 27.8% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 118,039 shares of the company's stock after selling 45,424 shares during the period. Bamco Inc. NY's holdings in Elanco Animal Health were worth $2,905,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Elanco Animal Health in the 1st quarter valued at about $2,065,000. Goldman Sachs Group Inc. raised its stake in shares of Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock worth $50,268,000 after purchasing an additional 2,445,872 shares in the last quarter. Empowered Funds LLC raised its stake in shares of Elanco Animal Health by 35.2% during the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company's stock worth $166,000 after purchasing an additional 4,121 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Elanco Animal Health by 4.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company's stock valued at $18,830,000 after acquiring an additional 76,408 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its stake in Elanco Animal Health by 2,006.9% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company's stock valued at $4,432,000 after purchasing an additional 295,651 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ELAN shares. Piper Sandler reaffirmed an "overweight" rating on shares of Elanco Animal Health in a report on Monday, June 29th. Citigroup increased their price target on Elanco Animal Health from $30.00 to $31.00 and gave the stock a "buy" rating in a research report on Thursday, May 7th. TD Cowen raised their price objective on Elanco Animal Health from $31.00 to $32.00 and gave the stock a "buy" rating in a research note on Thursday, June 18th. UBS Group raised their price objective on Elanco Animal Health from $31.00 to $33.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Finally, JPMorgan Chase & Co. upped their target price on Elanco Animal Health from $28.00 to $30.00 and gave the company an "overweight" rating in a research report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $29.09.

Elanco Animal Health Stock Down 2.2%

Shares of NYSE:ELAN opened at $24.52 on Friday. Elanco Animal Health Incorporated has a 52-week low of $17.11 and a 52-week high of $27.98. The company has a fifty day moving average of $24.62 and a 200-day moving average of $24.01. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. The company has a market capitalization of $12.25 billion, a PE ratio of -59.80, a price-to-earnings-growth ratio of 1.50 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The company had revenue of $1.37 billion for the quarter, compared to analysts' expectations of $1.31 billion. During the same period in the previous year, the business posted $0.26 earnings per share. The business's quarterly revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, equities analysts predict that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.

Insider Buying and Selling at Elanco Animal Health

In other news, Director Lawrence Erik Kurzius acquired 40,000 shares of the firm's stock in a transaction dated Thursday, August 20th. The stock was bought at an average cost of $23.40 per share, for a total transaction of $936,000.00. Following the completion of the transaction, the director directly owned 188,647 shares in the company, valued at $4,414,339.80. This represents a 26.91% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Paul Herendeen bought 10,000 shares of the company's stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average price of $23.68 per share, for a total transaction of $236,800.00. Following the acquisition, the director owned 111,687 shares of the company's stock, valued at $2,644,748.16. This trade represents a 9.83% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased 63,198 shares of company stock worth $1,473,109 over the last 90 days. Company insiders own 1.14% of the company's stock.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source